ImmuPharma plc (LON:IMM – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 5.84 and traded as low as GBX 4.34. ImmuPharma shares last traded at GBX 4.44, with a volume of 1,370,758 shares traded.
ImmuPharma Stock Performance
The company has a market capitalization of £27.67 million, a price-to-earnings ratio of -11.99 and a beta of 2.98. The company has a 50-day moving average price of GBX 4.47 and a 200-day moving average price of GBX 5.84.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. As a group, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
